PT3877395T - Processo industrial para a preparação de estetrol de pureza elevada - Google Patents

Processo industrial para a preparação de estetrol de pureza elevada

Info

Publication number
PT3877395T
PT3877395T PT207683988T PT20768398T PT3877395T PT 3877395 T PT3877395 T PT 3877395T PT 207683988 T PT207683988 T PT 207683988T PT 20768398 T PT20768398 T PT 20768398T PT 3877395 T PT3877395 T PT 3877395T
Authority
PT
Portugal
Prior art keywords
estetrol
preparation
high purity
industrial process
industrial
Prior art date
Application number
PT207683988T
Other languages
English (en)
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PT3877395T publication Critical patent/PT3877395T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT207683988T 2019-09-03 2020-09-02 Processo industrial para a preparação de estetrol de pureza elevada PT3877395T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1900315A HU231240B1 (hu) 2019-09-03 2019-09-03 Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Publications (1)

Publication Number Publication Date
PT3877395T true PT3877395T (pt) 2023-02-02

Family

ID=89992977

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207683988T PT3877395T (pt) 2019-09-03 2020-09-02 Processo industrial para a preparação de estetrol de pureza elevada

Country Status (32)

Country Link
US (1) US11633406B2 (pt)
EP (1) EP3877395B1 (pt)
JP (1) JP7265087B2 (pt)
KR (1) KR102871606B1 (pt)
CN (1) CN114302889B (pt)
AU (1) AU2020343497B2 (pt)
CA (1) CA3147815C (pt)
CL (1) CL2022000492A1 (pt)
CO (1) CO2022003769A2 (pt)
CU (1) CU24692B1 (pt)
DK (1) DK3877395T3 (pt)
EC (1) ECSP22022403A (pt)
ES (1) ES2855923T3 (pt)
FI (1) FI3877395T3 (pt)
GE (1) GEP20247626B (pt)
HR (1) HRP20230230T1 (pt)
HU (2) HU231240B1 (pt)
IL (1) IL290973B2 (pt)
JO (1) JOP20220041A1 (pt)
LT (1) LT3877395T (pt)
MA (1) MA54200B1 (pt)
MD (1) MD3877395T2 (pt)
MX (1) MX2022002603A (pt)
MY (1) MY206905A (pt)
PE (1) PE20221418A1 (pt)
PH (1) PH12022550388A1 (pt)
PL (1) PL3877395T3 (pt)
PT (1) PT3877395T (pt)
RS (1) RS63966B1 (pt)
SI (1) SI3877395T1 (pt)
WO (1) WO2021044302A1 (pt)
ZA (1) ZA202203557B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112020004564T5 (de) * 2019-09-27 2022-06-15 Industriale Chimica S.R.L. VERFAHREN ZUM HERSTELLEN VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIEN-3,15,16,17-TETROL (ESTETROL) UND ZWISCHENSTUFEN DES VERFAHRENS
HU231651B1 (hu) * 2021-10-01 2025-05-28 Industriale Chimica S.R.L. Eljárás (15alfa,16alfa,17béta)-ösztra-1,3,5(10)-trién-3,15,16,17-tetrol (esztetrol) és esztetrol-monohidrát előállítására
JP2026503158A (ja) * 2023-02-02 2026-01-27 インダストリアーレ キミカ エッセ.エッレ.エッレ. (15α,16α,17β)-エストラ-1,3,5(10)-トリエン-3,15,16,17-テトロール(エステトロール)一水和物の調製方法
CN117088928B (zh) * 2023-08-16 2025-09-09 湖北共同甾体药物研究院有限公司 用于制备高纯度雌四醇的工艺
CN119569803B (zh) * 2023-09-05 2025-09-16 秦皇岛紫竹药业有限公司 一种制备高纯度雌四醇的方法
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás
CN119112905B (zh) * 2024-09-10 2026-07-28 武汉九珑人福药业有限责任公司 含雌孕激素的药物组合物、药物制剂及其制备方法、应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
DE60234515D1 (de) 2001-05-23 2010-01-07 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
DE60216630T2 (de) 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
SI1511496T1 (sl) 2002-06-11 2007-04-30 Pantarhei Bioscience Bv Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
EP1526856B1 (en) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
WO2004037269A1 (en) 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CN100343269C (zh) * 2002-11-08 2007-10-17 潘塔希生物科学股份有限公司 通过雌酮衍生的甾体化合物合成雌四醇
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
EP2383279A1 (en) * 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CA2843951C (en) 2011-08-11 2019-08-06 Wout WOUTERS Use of estetrol as emergency contraceptive
AU2012320423C1 (en) * 2011-10-07 2018-01-25 Estetra Srl Process for the production of estetrol
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2013034780A2 (en) * 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
ES2624667T3 (es) * 2013-09-18 2017-07-17 Crystal Pharma, S.A.U. Procedimiento para la preparación de estetrol
DK3079671T3 (en) 2013-12-12 2017-12-11 Donesta Bioscience B V Orally disintegrating solid dosage unit containing an estetrol component
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
SG11202000881VA (en) 2017-08-01 2020-02-27 Fund Sa Adjuvant therapy for use in prostate cancer treatment
IL276584B2 (en) 2018-02-07 2024-10-01 Estetra Srl Contraceptive composition with reduced cardiovascular effects
DE112020004564T5 (de) 2019-09-27 2022-06-15 Industriale Chimica S.R.L. VERFAHREN ZUM HERSTELLEN VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIEN-3,15,16,17-TETROL (ESTETROL) UND ZWISCHENSTUFEN DES VERFAHRENS

Also Published As

Publication number Publication date
FI3877395T3 (fi) 2023-03-18
MY206905A (en) 2025-01-15
DK3877395T3 (da) 2023-03-06
ES2855923T3 (es) 2023-04-28
GEP20247626B (en) 2024-05-27
RS63966B1 (sr) 2023-03-31
CO2022003769A2 (es) 2022-04-19
MD3877395T2 (ro) 2023-05-31
JP7265087B2 (ja) 2023-04-25
WO2021044302A1 (en) 2021-03-11
HU231240B1 (hu) 2022-04-28
SI3877395T1 (sl) 2023-03-31
HRP20230230T1 (hr) 2023-04-14
EP3877395B1 (en) 2022-12-07
BR112022003254A2 (pt) 2022-05-17
EP3877395A1 (en) 2021-09-15
CU24692B1 (es) 2024-01-10
HUE061427T2 (hu) 2023-07-28
KR102871606B1 (ko) 2025-10-16
CN114302889A (zh) 2022-04-08
CL2022000492A1 (es) 2023-03-10
MX2022002603A (es) 2022-03-25
ZA202203557B (en) 2022-11-30
PE20221418A1 (es) 2022-09-20
MA54200A (fr) 2022-04-27
PH12022550388A1 (en) 2024-01-29
NZ786568A (en) 2026-01-30
AU2020343497B2 (en) 2023-02-02
LT3877395T (lt) 2023-02-27
AU2020343497A1 (en) 2022-04-14
US11633406B2 (en) 2023-04-25
KR20220071206A (ko) 2022-05-31
US20220296609A1 (en) 2022-09-22
ECSP22022403A (es) 2022-04-29
IL290973B1 (en) 2023-07-01
JP2022546016A (ja) 2022-11-02
PL3877395T3 (pl) 2023-05-08
MA54200B1 (fr) 2023-02-28
CN114302889B (zh) 2023-08-29
HUP1900315A1 (hu) 2021-03-29
JOP20220041A1 (ar) 2023-01-30
ES2855923T1 (es) 2021-09-24
CA3147815A1 (en) 2021-03-11
CA3147815C (en) 2023-03-28
IL290973B2 (en) 2023-11-01
IL290973A (en) 2022-05-01
CU20220013A7 (es) 2022-10-11

Similar Documents

Publication Publication Date Title
ZA202203557B (en) Industrial process for the preparation of high purity estetrol
IL276917A (en) A process for the preparation of alubixivet
SG11202005382YA (en) Process for the preparation of microcapsules
GB2593352B (en) Process for the preparation of 3alpha-hydroxy-5alpha-pregnan-20-one (brexanolone)
IL289904B1 (en) Process for preparing biphenylamines
IL289453B2 (en) Process for preparing ridinilazole and its crystalline forms
IL268835B (en) A process for the preparation of 2-cyanoimidazole compounds
SG11202108238VA (en) Process for the preparation of methionine
PL3765440T3 (pl) Sposób wytwarzania n-alkilonitratoetylonitroamin
SG11202101575TA (en) Process for the production of high purity isobutylene
IL285550A (en) Process for preparing polyamides
IL281254A (en) A process for the preparation of lanbatinib
IL275480A (en) A process for the preparation of pyrimidinyl-4-aminopyrazole compounds
HUE064707T2 (hu) Eljárás nagy tisztaságú midosztaurin elõállítására
IL283633A (en) A process for preparing a cyclic dinucleotide
IL290181B2 (en) Process for preparing fluonesulfone
PL3599256T3 (pl) Sposób wytwarzania poliorganosiloksanów
PL3458522T3 (pl) Proces otrzymywania związków diaminofenotiazynowych o wysokim stopniu czystości
HUP2300098A1 (hu) Eljárás upadacitinib elõállítására
IL290215A (en) A process for the preparation of crystalline form ii of sotagliflozin
IL286054A (en) A process for the preparation of a modified imidazoquinoline
IL279410A (en) Process for preparing Quinmark
HUP1800278A2 (en) Process for the preparation of boc-linagliptin
IL325770A (en) Process for the preparation of thiophenones
IL326079A (en) Process for preparing beta-hydroxyketones